Securian Asset Management Inc. Cuts Stock Holdings in Zoetis Inc. (NYSE:ZTS)

Securian Asset Management Inc. trimmed its position in shares of Zoetis Inc. (NYSE:ZTS) by 3.0% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 26,236 shares of the company’s stock after selling 804 shares during the quarter. Securian Asset Management Inc.’s holdings in Zoetis were worth $4,548,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. Private Wealth Management Group LLC purchased a new position in shares of Zoetis during the 4th quarter valued at approximately $33,000. Webster Bank N. A. increased its holdings in shares of Zoetis by 89.1% during the 1st quarter. Webster Bank N. A. now owns 174 shares of the company’s stock valued at $29,000 after purchasing an additional 82 shares in the last quarter. Gladius Capital Management LP purchased a new position in shares of Zoetis during the 4th quarter valued at approximately $40,000. Neo Ivy Capital Management purchased a new position in shares of Zoetis during the 4th quarter valued at approximately $40,000. Finally, EdgeRock Capital LLC acquired a new stake in Zoetis in the 4th quarter valued at $45,000. 92.80% of the stock is owned by hedge funds and other institutional investors.

Zoetis Price Performance

ZTS traded down $1.93 on Monday, hitting $183.32. 686,302 shares of the company’s stock were exchanged, compared to its average volume of 2,777,081. Zoetis Inc. has a fifty-two week low of $144.80 and a fifty-two week high of $201.92. The company has a current ratio of 3.45, a quick ratio of 2.09 and a debt-to-equity ratio of 1.32. The firm has a 50-day moving average price of $176.79 and a 200-day moving average price of $175.31. The stock has a market cap of $83.05 billion, a price-to-earnings ratio of 35.69, a P/E/G ratio of 2.84 and a beta of 0.86.

Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Tuesday, August 6th. The company reported $1.56 EPS for the quarter, topping the consensus estimate of $1.49 by $0.07. Zoetis had a return on equity of 50.67% and a net margin of 26.29%. The business had revenue of $2.36 billion for the quarter, compared to analyst estimates of $2.31 billion. During the same quarter in the previous year, the firm earned $1.41 EPS. The company’s quarterly revenue was up 8.3% compared to the same quarter last year. As a group, equities analysts anticipate that Zoetis Inc. will post 5.84 earnings per share for the current year.

Zoetis Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, September 4th. Stockholders of record on Thursday, July 18th will be issued a dividend of $0.432 per share. The ex-dividend date of this dividend is Thursday, July 18th. This represents a $1.73 annualized dividend and a dividend yield of 0.94%. Zoetis’s dividend payout ratio is presently 33.33%.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on ZTS shares. Barclays dropped their price target on shares of Zoetis from $260.00 to $230.00 and set an “overweight” rating on the stock in a research note on Tuesday, April 23rd. BTIG Research started coverage on shares of Zoetis in a research note on Thursday, July 25th. They issued a “buy” rating and a $220.00 price target on the stock. The Goldman Sachs Group dropped their price target on shares of Zoetis from $223.00 to $196.00 and set a “buy” rating on the stock in a research note on Monday, May 6th. Piper Sandler reissued an “overweight” rating and issued a $195.00 price target (down previously from $220.00) on shares of Zoetis in a research note on Tuesday, April 16th. Finally, Stifel Nicolaus lifted their price target on shares of Zoetis from $180.00 to $200.00 and gave the company a “buy” rating in a research note on Monday, August 5th. Nine investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $214.89.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.